NEWS
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System, making them eligible for Zephyr® Valve treatment. These patients experienced improvements in lung function, quality of life, and treated lobe volume reduction.
The 5-year follow-up data from the LIBERATE study demonstrated durable improvements in lung function for patients treated with Zephyr Valves, with FEV1 improvements ranging from 109 mL in Year 1 to 79 mL at Year 5. The study also showed an acceptable safety profile and a 38% mortality rate over 5 years, lower than historical medically managed control patients.
The 5-year follow-up data from the LIBERATE study demonstrated durable improvements in lung function for patients treated with Zephyr Valves, with FEV1 improvements ranging from 109 mL in Year 1 to 79 mL at Year 5. The study also showed an acceptable safety profile and a 38% mortality rate over 5 years, lower than historical medically managed control patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2862Followers
108Following
30KVisitors
Follow